Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory...
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.